Loading clinical trials...
Loading clinical trials...
Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Released by Interventional Approaches for Advanced Solid Tumors
To study the safety and clinical effects of intratumor injecting CpG-ODN and in situ release of tumor antigen by interventional ablation or drug-eluting beads to treat advanced solid tumors.
1. Percutaneous microwave ablation or intratumor injection of drug-eluting beads to destroy cancer cells to release tumor-specific antigens 2. Intratumor injection of type A/C CpG-ODN with or without infusion of CAR-T cells secreting scFv against OX40 3. Assessing side effects and therapeutic efficacy after the combined treatments
Age
18 - 80 years
Sex
ALL
Healthy Volunteers
No
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Start Date
March 1, 2021
Primary Completion Date
June 30, 2029
Completion Date
June 30, 2036
Last Updated
June 26, 2024
50
ESTIMATED participants
CpG-ODN
COMBINATION_PRODUCT
Lead Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Collaborators
NCT06811116
NCT07190248
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions